• Cancer drug developer Anixa Biosciences (NASDAQ:ANIX) traded higher on Friday after the company's board of directors approved the purchase of Bitcoin as a treasury reserve asset to diversify its financial position.
• "With Anixa's strong balance sheet and excess cash, this strategic decision aims to diversify the company's treasury holdings while positioning Anixa to benefit from the potential long-term value of digital assets," the company said.
• "Our decision about Bitcoin is an additional approach to prudent financial management, enabling greater shareholder value," CEO Amit Kumar added.
• CFO Mike Catelani said that Bitcoin is a valuable addition to the company's treasury management strategy, given its recognition as a mainstream asset class.
• Additionally, the company reiterated its commitment to the ongoing stock buyback program, which it said implied its commitment to improve shareholder value.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。